3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Taste Disorders
1
Parasomnias
1
Pain
1
Olfaction Disorders
1
Neoplasms
1
Nausea
1
Marijuana Abuse
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Cancer Pain
1
Breast Neoplasms
1
Anxiety Disorders
1
Anorexia
1
Interventions
Psilocybin
5
Psychotherapy
2
Fluoxetine
2
Cannabidiol
2
nabiximols
1
Yoga
1
Therapeutics
1
Sertraline
1
Self-Management
1
Selective Serotonin Reuptake Inhibitors
1
Professional Autonomy
1
Pharmaceutical Preparations
1
Niacin
1
Neoadjuvant Therapy
1
N-Methyl-3,4-methylenedioxyamphetamine
1
Minocycline
1
Medical Marijuana
1
Ketamine
1
Injections
1
Hormones
1
Gemcitabine
1
Exercise
1
Dronabinol
1
Donepezil
1
Clomipramine
1
Citalopram
1
Cisplatin
1
Aromatherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anxiety Disorders
×
Dronabinol
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled